All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma

October 2nd 2025

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Is AI Augmentation Driving Smarter, Better Cancer Care?

October 2nd 2025

Four experts share their perspectives on the potential challenges and future directions for AI integration in the field of oncology.

Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025

October 2nd 2025

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Neoadjuvant Daromun Yields Improved Recurrence-Free Survival in Locally Advanced Melanoma

October 2nd 2025

Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.

From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma

October 1st 2025

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

Emerging Strategies Aim to Enhance Safety and Monitoring in CAR T-Cell Therapy

October 1st 2025

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

Revisit Every OncLive On Air Episode From September 2025

October 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in September 2025.

UCSF Radiation Oncology Specialists Share Innovative Research and Clinical Expertise at National Radiation Oncology Conference

October 1st 2025

This year’s ASTRO program highlights research and expert discussions from UCSF Radiation Oncology and the Helen Diller Family Comprehensive Cancer Center.

FDA Grants Fast Track Designation to ETX-636 for PIK3CA-Mutant, HR+/HER2-Negative Breast Cancer

October 1st 2025

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

FDA Accepts sBLA for T-DXd Followed by THP in High-Risk, HER2+ Early-Stage Breast Cancer

October 1st 2025

The FDA accepted an sBLA seeking the approval of neoadjuvant T-DXd followed by THP for the management of high-risk, HER2-positive breast cancer.

Dual-Binding XmAb30819 Shows Strong Specificity in ENPP3-Positive RCC

October 1st 2025

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

How AI-Driven Platforms Can Transform Clinical Trial Efficiency in Cancer Care

October 1st 2025

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress

October 1st 2025

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

FDA Approves 2 Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 30th 2025

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

TKI Advances and Patient-Centered Decision-Making Guide the Path Toward Functional Cures in CML

September 30th 2025

Michael J. Mauro, MD, discusses the evolution of TKIs for CML, factors for TKI selection, and ways that genetic mutations influence treatment efficacy.

CCR4-Directed Strategy Achieves Durable Response in T-Cell Lymphoma Following Treatment with Anti-BCMA CAR T-Cell Therapy

September 30th 2025

Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.

Northwell Cancer Institute Unveils $14M Center for Women's Cancer, Creating an Integrated Care Model With Comprehensive Services in One Location

September 30th 2025

The Northwell Cancer Institute unveiled its Center for Women's Cancer at the R.J. Zuckerberg Cancer Center.

FDA Receives BLA Submission for the Approval of Pivekimab Sunirine for BPDCN

September 30th 2025

The FDA has received a BLA seeking the approval of pivekimab sunirine for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

FDA Grants Fast Track Designation to UB-VV111 for R/R B-Cell Malignancies

September 30th 2025

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Ropeginterferon Alfa-2b Generates Superior Efficacy vs Anagrelide in High-Risk Essential Thrombocythemia

September 30th 2025

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.